Geneplus-Beijing Co. Ltd.
31
9
12
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
3.2%
1 terminated/withdrawn out of 31 trials
80.0%
-6.5% vs industry average
3%
1 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (31)
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
Role: collaborator
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
Role: lead
Benign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(GM-seq)
Role: lead
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
Role: lead
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Role: lead
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Role: collaborator
Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer
Role: lead
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Role: lead
The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer
Role: lead
ctDNA Monitoring in Early Breast Cancer
Role: lead
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
Role: lead
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
Role: collaborator
Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer
Role: collaborator
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Role: lead
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Role: collaborator
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
Role: collaborator
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Role: collaborator
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
Role: collaborator
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
Role: collaborator
Primary Hepatobiliary Cancer Cohort of Central China
Role: collaborator